<DOC>
	<DOCNO>NCT00153803</DOCNO>
	<brief_summary>This national , randomize , web-based , double-blind study determine whether erlotinib ( Tarceva ) compare placebo improves progression-free survival ( PFS ) patient inoperable , stage III NSCLC follow concurrent docetaxel , carboplatin thoracic radiotherapy . We hypothesize introduction orally active , well-tolerated agent follow concurrent chemoradiation prior emergence drug resistance prolong progression-free survival 40 % ( 10 month â†’ 14 month ) .</brief_summary>
	<brief_title>Erlotinib Placebo Following Chemoradiotherapy ( Chemo/RT ) Stage III Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The promising activity erlotinib single agent advance refractory NSCLC along oral administration favorable adverse event profile make agent excellent candidate incorporate combine modality therapy early stage lung cancer . Based data , erlotinib attractive novel approach maintenance therapy unresectable stage III NSCLC follow completion concomitant chemoradiation . Although , subset patient unresectable stage III NSCLC long-term survivor follow chemotherapy thoracic radiation therapy , vast majority relapse within first year follow therapy eventually die chemotherapy refractory disease . We hypothesize introduction potent tyrosine kinase inhibitor epidermal growth factor receptor follow effective concomitant chemoradiotherapy docetaxel carboplatin prolong progression-three survival time patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Unresectable , stage IIIA IIIB NSCLC ( measurable disease require ) No evidence metastatic disease No prior treatment Adequate organ function Adequate pulmonary function ( FEV &gt; = 1.0L predict FEV &gt; 0.8L ) Metastasis Prior treatment Malignant pleural pericardial effusion Peripheral neuropathy &gt; = grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Web base</keyword>
	<keyword>Stage III NSCLC</keyword>
</DOC>